Literature DB >> 30819906

Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: prevalence, characteristic and significance.

Rakchha Chhetri1,2, Li Yan A Wee1,2, Romi Sinha3, Monika M Kutyna2,4, Anh Pham5, Helen Stathopoulos5, Lakshmi Nath6, Shriram V Nath6,7, Nicholas Wickham8, Tim Hughes1,2,4, Deepak Singhal1,2,4, David J Roxby5,9, Devendra K Hiwase10,2,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30819906      PMCID： PMC6886410          DOI： 10.3324/haematol.2018.215087

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Coexistence of autoantibodies and alloantibodies to red blood cells due to blood transfusion.

Authors:  Norbert Ahrens; Axel Pruss; Andreas Kähne; Holger Kiesewetter; Abdulgabar Salama
Journal:  Transfusion       Date:  2007-05       Impact factor: 3.157

2.  Detecting alloantibodies in patients with autoantibodies.

Authors:  D R Branch; L D Petz
Journal:  Transfusion       Date:  1999-01       Impact factor: 3.157

3.  Red cell antibodies in frequently transfused patients with myelodysplastic syndrome.

Authors:  G Stiegler; W Sperr; C Lorber; V Fabrizii; P Höcker; S Panzer
Journal:  Ann Hematol       Date:  2001-06       Impact factor: 3.673

4.  Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly asian descent.

Authors:  S T Singer; V Wu; R Mignacca; F A Kuypers; P Morel; E P Vichinsky
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

5.  Warm reactive autoantibodies: clinical and serologic correlations.

Authors:  Christine A Wheeler; Loni Calhoun; Douglas P Blackall
Journal:  Am J Clin Pathol       Date:  2004-11       Impact factor: 2.493

6.  Immunohematological findings in myelodysplastic syndrome.

Authors:  M C Novaretti; C R Sopelete; E R Velloso; M F Rosa; P E Dorlhiac-Llacer; D A Chamone
Journal:  Acta Haematol       Date:  2001       Impact factor: 2.195

7.  Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.

Authors:  Cristina Sanz; Meritxell Nomdedeu; Mohamad Belkaid; Irene Martinez; Benet Nomdedeu; Arturo Pereira
Journal:  Transfusion       Date:  2012-07-31       Impact factor: 3.157

8.  Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome.

Authors:  Gláucia A S Guelsin; Camila Rodrigues; Jeane E L Visentainer; Paula De Melo Campos; Fabíola Traina; Simone C O Gilli; Sara T O Saad; Lilian Castilho
Journal:  Blood Transfus       Date:  2014-06-12       Impact factor: 3.443

9.  Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome.

Authors:  Deepak Singhal; Monika M Kutyna; Rakchha Chhetri; Li Yan A Wee; Sophia Hague; Lakshmi Nath; Shriram V Nath; Romi Sinha; Nicholas Wickham; Ian D Lewis; David M Ross; Peter G Bardy; Luen Bik To; John Reynolds; Erica M Wood; David J Roxby; Devendra K Hiwase
Journal:  Haematologica       Date:  2017-10-05       Impact factor: 9.941

10.  Clinical and epidemiological profile of alloimmunized and autoimmunized multi-transfused patients against red blood cell antigens in a blood center of Minas Gerais.

Authors:  Orsetti Gomes do Valle Neto; Vitor Mendonça Alves; Gilberto de Araújo Pereira; Helio Moraes-Souza; Paulo Roberto Juliano Martins
Journal:  Hematol Transfus Cell Ther       Date:  2018-02-17
View more
  1 in total

1.  A clinical effect of disease-modifying treatment on alloimmunisation in transfused patients with myelodysplastic syndromes: data from a population-based study.

Authors:  Johanne Rozema; Christiaan L Slim; Nic J G M Veeger; Robby E Kibbelaar; Harry de Wit; Eric N van Roon; Mels Hoogendoorn
Journal:  Blood Transfus       Date:  2020-12-16       Impact factor: 3.443
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.